Cerebellar Ataxia, Intellectual Disability, and Dysequilibrium Syndrome (CAMRQ / Dysequilibrium Syndrome): Comprehensive Research Report

Target disease

• Disease name (preferred): Cerebellar ataxia, intellectual disability, and dysequilibrium (CAMRQ spectrum) (beaudin2019thenosologyof pages 27-28, OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome)
• Category: Mendelian, neurodevelopmental disorder; typically autosomal recessive (beaudin2019thenosologyof pages 27-28, boycott2009mutationsinvldlr pages 1-2)
• MONDO ID: MONDO:0009133 (disease group) (OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome)
• Orphanet ID: Orphanet:1766 (“Dysequilibrium syndrome”) (OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome)

Executive summary (current understanding)

CAMRQ (also historically called dysequilibrium syndrome, DES) is a genetically heterogeneous group of congenital/early-onset neurodevelopmental disorders characterized by cerebellar ataxia/disequilibrium with intellectual disability and variable neuroimaging abnormalities (most classically inferior cerebellar hypoplasia with simplified gyration in VLDLR-associated disease, but MRI can be normal in ATP8A2-associated disease). Core pathophysiology differs by subtype but converges on disrupted neurodevelopmental circuitry (neuronal migration/synapse development for VLDLR; membrane lipid asymmetry/neuronal maintenance for ATP8A2; cerebellar circuit development for CA8; endosomal/autophagy-linked neuronal homeostasis for WDR81). Management is currently supportive (rehabilitation, educational support, feeding/respiratory management, symptomatic seizure management). (boycott2009mutationsinvldlr pages 1-2, boycott2009mutationsinvldlr pages 2-4, alsahli2018furtherdelineationof pages 1-2, narishige2022twosiblingswith pages 1-2, hochman2025cerebellarataxiaimpaired pages 1-2)

1. Disease information

1.1 What is the disease?

Dysequilibrium syndrome/CAMRQ is described as an autosomal recessive genetically heterogeneous condition with congenital onset, non-progressive cerebellar ataxia, disequilibrium, and intellectual disability, associated with cerebellar hypoplasia in many cases. (wali2021broadeningtheclinical pages 1-2, boycott2009mutationsinvldlr pages 1-2)

Direct abstract quote (authoritative definition): - “Dysequilibrium syndrome (DES) is an autosomal recessive genetically heterogeneous condition characterized clinically by congenital onset of non-progressive cerebellar ataxia, disturbed equilibrium and mental retardation associated with cerebellar hypoplasia.” (Movement Disorders Clinical Practice; May 2021; https://doi.org/10.1002/mdc3.13184) (wali2021broadeningtheclinical pages 1-2)

1.2 Key identifiers and synonyms

A harmonized identifier map supported by OpenTargets (for MONDO/Orphanet) and ataxia nosology literature (for OMIM subtype mapping) is summarized here:

Table: This table summarizes the disease-group and subtype nomenclature for cerebellar ataxia, intellectual disability, and dysequilibrium syndrome, including MONDO, Orphanet, OMIM, and gene mappings. It is useful for harmonizing disease knowledge base entries across aggregated rare-disease resources and subtype-specific literature.

Notes on missing identifiers: This tool-based evidence set did not contain explicit ICD-10/ICD-11 or MeSH IDs for CAMRQ/DES; these should be sourced from OMIM/Orphanet/MeSH directly during curation (not retrievable in the current evidence set). (beaudin2019thenosologyof pages 27-28, OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome)

1.3 Data provenance (individual vs aggregated)

• Aggregated resources: OpenTargets associations connecting Dysequilibrium syndrome (Orphanet:1766) and CAMRQ MONDO terms to genes (ATP8A2, VLDLR, WDR81, CA8) (OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome).
• Individual/family-level primary clinical genetics: numerous family/case-series reports for VLDLR-DES and ATP8A2-CAMRQ4 and rarer WDR81/CA8 subtypes (boycott2009mutationsinvldlr pages 1-2, narishige2022twosiblingswith pages 1-2, alsahli2018furtherdelineationof pages 1-2, hochman2025cerebellarataxiaimpaired pages 1-2).

2. Etiology

2.1 Disease causal factors

Primary cause is genetic (Mendelian, autosomal recessive) with multiple subtype genes: - CAMRQ1: VLDLR (VLDLR-associated cerebellar hypoplasia/dysequilibrium syndrome) (beaudin2019thenosologyof pages 27-28, boycott2009mutationsinvldlr pages 1-2) - CAMRQ2: WDR81 (beaudin2019thenosologyof pages 27-28, hochman2025cerebellarataxiaimpaired pages 1-2) - CAMRQ3: CA8 (beaudin2019thenosologyof pages 27-28, richmond2020cerebellarataxiawith pages 6-11) - CAMRQ4: ATP8A2 (beaudin2019thenosologyof pages 27-28, alsahli2018furtherdelineationof pages 1-2)

2.2 Risk factors

• Consanguinity is frequently reported for CAMRQ4 cohorts (e.g., “consanguinity in 90%” in one CAMRQ4 cohort) (alsahli2018furtherdelineationof pages 1-2).
• Population clustering/founder effects are reported for specific VLDLR variants (e.g., Hutterite population; founder mutation in Oman) (boycott2009mutationsinvldlr pages 1-2, ali2012amissensefounder pages 1-3).

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No CAMRQ-specific gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

3.1 Core clinical phenotype and frequencies (with HPO)

Quantitative phenotype frequencies are best described for CAMRQ4 (ATP8A2) cohorts; VLDLR-DES has classic imaging plus selected frequency estimates (e.g., seizures). A phenotype/HPO mapping table with frequencies is provided:

Table: This table summarizes the most consistently reported clinical and MRI phenotypes across CAMRQ/dysequilibrium syndrome, with HPO mappings and subtype associations. It emphasizes quantitative frequencies from CAMRQ4 cohorts and the classic neuroradiologic pattern of VLDLR-associated disease.

3.2 Key neuroradiologic signature (VLDLR subtype)

VLDLR-associated disease has a recognizable MRI pattern including inferior cerebellar vermis/hemisphere hypoplasia and simplified gyration. Figure-level evidence was captured from Boycott et al. (2009) showing these characteristic findings. (boycott2009mutationsinvldlr media 6fdfc298)

3.3 Quality-of-life impact

Direct quality-of-life instrument data (EQ-5D/SF-36/PROMIS) were not identified in the retrieved literature. However, the high frequency of non-ambulation and feeding difficulties in CAMRQ4 indicates substantial functional dependence. (narishige2022twosiblingswith pages 4-5, narishige2022twosiblingswith pages 2-4)

4. Genetic / molecular information

4.1 Causal genes

Causal gene mapping for the CAMRQ spectrum is supported by ataxia nosology and OpenTargets disease–gene associations (beaudin2019thenosologyof pages 27-28, OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome).

4.2 Pathogenic variants (examples) and functional class

Representative pathogenic variants and mechanistic themes are summarized:

Table: This table summarizes representative CAMRQ subtype genes, example pathogenic variants, and the main mechanistic themes supported by human and functional evidence. It is useful for linking subtype-specific variants to shared and distinct neurodevelopmental pathways relevant to diagnosis and interpretation.

Key examples: - VLDLR (CAMRQ1): compound heterozygous variants p.(Asp521His) and p.(Tyr571Leufs7) reported as causal in non-Hutterite family; consistent with autosomal recessive disease (Journal of Child Neurology; Mar 2009; https://doi.org/10.1177/0883073809332696) (boycott2009mutationsinvldlr pages 2-4, boycott2009mutationsinvldlr media 6fdfc298). - ATP8A2 (CAMRQ4): compound heterozygous truncating variants p.(Arg581) and p.(Arg720*) in severe early-onset cases (Tohoku J Exp Med; Mar 2022; https://doi.org/10.1620/tjem.2022.j010) (narishige2022twosiblingswith pages 1-2).

4.3 Variant class, population frequency, and somatic/germline

• Evidence supports germline biallelic pathogenic variants as causal; somatic mechanisms are not implicated in the retrieved CAMRQ evidence. (boycott2009mutationsinvldlr pages 1-2, narishige2022twosiblingswith pages 1-2)
• This evidence set did not include allele frequencies from gnomAD/ExAC; such frequencies require external database query.

4.4 Modifier genes / epigenetics

No validated modifier genes or CAMRQ-specific epigenetic signatures were identified in the retrieved evidence.

5. Environmental information

No CAMRQ-specific environmental, lifestyle, or infectious causal factors were identified in the retrieved evidence; CAMRQ is best supported as a primary genetic neurodevelopmental disorder. (wali2021broadeningtheclinical pages 1-2, alsahli2018furtherdelineationof pages 1-2)

6. Mechanism / pathophysiology

6.1 Unifying disease model (causal chain)

1. Biallelic loss-of-function or deleterious missense variants in subtype genes (VLDLR/WDR81/CA8/ATP8A2). (beaudin2019thenosologyof pages 27-28, boycott2009mutationsinvldlr pages 1-2)
2. Gene-specific molecular dysfunction:
3. VLDLR: impaired Reelin signaling affecting neuronal migration and cortical/cerebellar development (boycott2009mutationsinvldlr pages 2-4, onat2012identificationofatp8a2a pages 155-159).
4. ATP8A2: impaired P4-ATPase lipid flippase activity and/or protein misfolding, disrupting membrane asymmetry, vesicle trafficking, and neuronal maintenance (alsahli2018furtherdelineationof pages 1-2, matsell2024functionalandin pages 1-3, narishige2022twosiblingswith pages 1-2).
5. CA8: loss of CA8 function (often via NMD) with downstream disruption of cerebellar circuit development; mouse data supports Purkinje/granule-cell circuit effects (richmond2020cerebellarataxiawith pages 6-11).
6. WDR81: associated with CAMRQ2; broader functional literature links WDR81 to neuronal homeostasis mechanisms including autophagy/endosomal biology (hochman2025cerebellarataxiaimpaired pages 1-2, matsell2025characterizingthefunctiona pages 108-112).
7. Systems-level neurodevelopmental outcomes: cerebellar hypoplasia/atrophy and altered cerebro-cerebellar circuitry.
8. Clinical manifestations: congenital/early onset ataxia/disequilibrium, delayed/absent ambulation (sometimes quadrupedal locomotion), hypotonia, and intellectual disability. (boycott2009mutationsinvldlr pages 1-2, narishige2022twosiblingswith pages 4-5)

6.2 Pathways and suggested ontology terms

• VLDLR/Reelin pathway: neuronal migration and cerebellar development.
• Suggested GO: GO:0001764 (neuron migration), GO:0021549 (cerebellum development).
• ATP8A2 lipid flipping / membrane asymmetry: phospholipid transport and protein folding quality control when misfolding.
• Suggested GO: GO:0006869 (lipid transport), GO:0006457 (protein folding).
• CA8 cerebellar circuit development: Purkinje/granule-cell development.
• Suggested GO: GO:0021549 (cerebellum development).

6.3 Cell types (Cell Ontology suggestions)

Evidence in this set implicates cerebellar circuitry and (for CA8) Purkinje cell circuit patterning; suggested CL terms: - Purkinje neuron: CL:0000121 - Cerebellar granule cell: CL:0000120

6.4 Molecular profiling / omics

No CAMRQ-specific transcriptomic/proteomic/metabolomic cohort profiling was retrieved. A CA8 case report highlighted FDG-PET hypometabolism as a potential early marker despite normal MRI, but this is imaging-metabolic rather than molecular omics. (paternoster2020novelhomozygousvariant pages 1-2)

7. Anatomical structures affected

7.1 Organ/system level

• Primary system: central nervous system—cerebellum and associated brainstem/cortical development (boycott2009mutationsinvldlr pages 2-4, boycott2009mutationsinvldlr media 6fdfc298).

7.2 Tissue/cell level

• Cerebellar cortex circuits (Purkinje and granule cell-related circuitry) (richmond2020cerebellarataxiawith pages 6-11).

7.3 Subcellular level (selected)

• ATP8A2-related: plasma membrane/Golgi/endosome lipid asymmetry and protein folding/trafficking (alsahli2018furtherdelineationof pages 1-2, matsell2024functionalandin pages 1-3).

7.4 UBERON suggestions

• Cerebellum: UBERON:0002037
• Cerebellar vermis: UBERON:0001305
• Pons: UBERON:0000974

8. Temporal development

• Onset: typically congenital/infancy. (boycott2009mutationsinvldlr pages 1-2, wali2021broadeningtheclinical pages 1-2)
• Course: often characterized as non-progressive (particularly in classic DES/VLDLR descriptions), but severity and evolution vary; some CAMRQ4 reports note degenerative features in imaging summaries. (micalizzi2016verymildfeatures pages 1-2, narishige2022twosiblingswith pages 4-5)

9. Inheritance and population

9.1 Inheritance

• Predominantly autosomal recessive across subtypes (VLDLR, WDR81, CA8, ATP8A2). (beaudin2019thenosologyof pages 27-28, alsahli2018furtherdelineationof pages 1-2, hochman2025cerebellarataxiaimpaired pages 1-2)

9.2 Epidemiology and populations (limited quantitative prevalence data)

Formal prevalence/incidence estimates were not identified in the retrieved evidence. Published case aggregates suggest extreme rarity: - For VLDLR-associated DES, one report noted “Approximately 50 genetically proven cases have been published to date” (as of May 2021). (wali2021broadeningtheclinical pages 1-2) - CAMRQ2 has been described as “fewer than 20 published cases” in a recent case report (note: case-report statement). (hochman2025cerebellarataxiaimpaired pages 1-2)

Reported populations/founder contexts include: - North American Hutterites (historic VLDLR deletion cohort), and additional families with Turkish, Iranian, Iraqi, Caucasian, Indian, and Omani background. (boycott2009mutationsinvldlr pages 1-2, wali2021broadeningtheclinical pages 1-2, ali2012amissensefounder pages 1-3)

10. Diagnostics

A practical diagnostic and differential approach is summarized here:

Table: This table summarizes the practical diagnostic workup and key differential diagnoses for cerebellar ataxia, intellectual disability, and dysequilibrium syndrome across major subtypes. It highlights where MRI is informative, where it may be misleading, and why broad genomic testing is central to diagnosis.

Key points for real-world implementation: - MRI pattern can be highly informative for VLDLR disease (inferior cerebellar hypoplasia + simplified gyration) (boycott2009mutationsinvldlr media 6fdfc298). - Normal MRI does not exclude CAMRQ4 (ATP8A2), and WES may be indicated even when imaging is non-diagnostic. (alsahli2018furtherdelineationof pages 1-2) - CAMRQ4 can mimic dyskinetic cerebral palsy early; sensory involvement (vision/hearing) and genomic testing help resolve diagnosis. (narishige2022twosiblingswith pages 1-2)

11. Outcome / prognosis

• Functional outcomes are variable by subtype and variant severity.
• In a CAMRQ4 cohort, severe disability was common and 2/10 deaths were attributed to “recurrent respiratory infection.” (alsahli2018furtherdelineationof pages 3-5)
• CAMRQ2 case report suggested early diagnosis and therapies may contribute to milder presentation and “more favorable outcome” (author interpretation). (hochman2025cerebellarataxiaimpaired pages 2-3)

12. Treatment

12.1 Current standard of care (supportive)

No disease-modifying pharmacotherapy was identified in the retrieved evidence; care is symptomatic and supportive: - Rehabilitation therapies: physical therapy / occupational therapy (CAMRQ2 case). (hochman2025cerebellarataxiaimpaired pages 1-2) - Educational supports: tutoring/special needs schooling and structured daily care support described in CAMRQ2 and CAMRQ4 cases. (hochman2025cerebellarataxiaimpaired pages 1-2, narishige2022twosiblingswith pages 1-2) - Seizure management: valproic acid used for suspected epilepsy in CAMRQ4. (narishige2022twosiblingswith pages 1-2) - Feeding management: feeding adaptations and monitoring for choking/feeding difficulty are described (CAMRQ2/CAMRQ4). (hochman2025cerebellarataxiaimpaired pages 1-2, narishige2022twosiblingswith pages 1-2)

12.2 MAXO term suggestions (for knowledge base annotation)

• Physical therapy: MAXO:0000010
• Occupational therapy: MAXO:0000011
• Speech therapy evaluation/therapy: MAXO:0000012
• Antiseizure medication therapy: MAXO:0001026 (broad category; exact MAXO mapping may vary by ontology version)
• Special education services: MAXO:0000127 (or related educational intervention term; verify in MAXO version used)

12.3 Experimental / targeted therapies

No CAMRQ-specific interventional clinical trials were identified in the retrieved ClinicalTrials.gov query results; hits appeared unrelated to CAMRQ genetics and likely reflect the ambiguity of “disequilibrium” as a symptom term. (clinical trials tool output; no CAMRQ-relevant trial context IDs available)

13. Prevention

Primary prevention is not established (genetic disease), but recurrence risk reduction is feasible through: - Genetic counseling after molecular diagnosis. - Carrier testing and reproductive planning; one CA8 case explicitly noted the diagnosis “informed reproductive planning.” (richmond2020cerebellarataxiawith pages 6-11)

14. Other species / natural disease

No naturally occurring veterinary CAMRQ/DES analogs were identified in the retrieved evidence.

15. Model organisms

Model evidence supports subtype mechanisms: - CA8: spontaneous wdl mouse model supports CA8 loss-of-function with ataxic phenotype and cerebellar circuit abnormalities (Purkinje/granule cell patterning). (richmond2020cerebellarataxiawith pages 6-11) - ATP8A2: mouse data summarized in foundational ATP8A2 work indicates neurologic phenotypes (ataxia/tremor) and axonal transport defects with Atp8a2 deficiency. (onat2012identificationofatp8a2 pages 155-159)

Recent developments (prioritizing 2023–2024)

1. 2024 functional interpretation of ATP8A2 variants (CAMRQ4): Disease Models & Mechanisms (Apr 2024; https://doi.org/10.1242/dmm.050546) experimentally distinguished misfolding variants from likely non-causative variants, supporting improved variant interpretation and (future) proteostasis-directed rescue strategies. (matsell2024functionalandin pages 1-3)
2. 2024 CAMRQ4 missense variant spectrum expansion: Neurogenetics (Jul 2024; https://doi.org/10.1007/s10048-024-00773-9) reported a novel ATP8A2 missense variant p.(Leu538Pro) with near-complete loss of protein expression and described diffusion MRI abnormalities, broadening imaging correlates. (flannery2024anovelmissense pages 1-5)
3. 2023 CAMRQ4 case report with novel compound heterozygosity: PRILOZI (Dec 2023; https://doi.org/10.2478/prilozi-2023-0051) reported a novel ATP8A2 frameshift in trans with a known stop variant, with white matter/corpus callosum abnormalities on MRI, adding to the allelic spectrum. (teov2023compoundheterozygosityin pages 1-3)

Limitations of this tool-based report

• ICD-10/ICD-11 and MeSH identifiers, gnomAD allele frequencies, and comprehensive epidemiology (prevalence/incidence) were not present in the retrieved evidence set and should be added by querying the recommended external resources (OMIM, Orphanet, MeSH, gnomAD) during knowledge base population.
• CAMRQ subtypes 2 and 3 are underrepresented in the retrieved primary literature compared with CAMRQ1 and CAMRQ4; additional targeted retrieval may be needed for complete frequency tables outside ATP8A2 cohorts.

References

1. (beaudin2019thenosologyof pages 27-28): M Beaudin. The nosology of hereditary cerebellar ataxias: development of a classification for recessive ataxias and phenotypical description of spinocerebellar ataxia 34. Unknown journal, 2019.

2. (OpenTargets Search: Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome): Open Targets Query (Dysequilibrium syndrome,cerebellar ataxia intellectual disability dysequilibrium syndrome, 17 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

3. (boycott2009mutationsinvldlr pages 1-2): Kym M. Boycott, Carsten Bonnemann, Joachim Herz, Stephanie Neuert, Chandree Beaulieu, James N. Scott, Anuradha Venkatasubramanian, and Jillian S. Parboosingh. Mutations in vldlr as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome). Journal of Child Neurology, 24:1310-1315, Mar 2009. URL: https://doi.org/10.1177/0883073809332696, doi:10.1177/0883073809332696. This article has 80 citations and is from a peer-reviewed journal.

4. (boycott2009mutationsinvldlr pages 2-4): Kym M. Boycott, Carsten Bonnemann, Joachim Herz, Stephanie Neuert, Chandree Beaulieu, James N. Scott, Anuradha Venkatasubramanian, and Jillian S. Parboosingh. Mutations in vldlr as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome). Journal of Child Neurology, 24:1310-1315, Mar 2009. URL: https://doi.org/10.1177/0883073809332696, doi:10.1177/0883073809332696. This article has 80 citations and is from a peer-reviewed journal.

5. (alsahli2018furtherdelineationof pages 1-2): Saud Alsahli, Muhammad Talal Alrifai, Saeed Al Tala, Fuad Al Mutairi, and Majid Alfadhel. Further delineation of the clinical phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome type 4. Journal of Central Nervous System Disease, Feb 2018. URL: https://doi.org/10.1177/1179573518759682, doi:10.1177/1179573518759682. This article has 30 citations and is from a peer-reviewed journal.

6. (narishige2022twosiblingswith pages 1-2): Yuta Narishige, Hisao Yaoita, Moriei Shibuya, Miki Ikeda, Kaori Kodama, Aritomo Kawashima, Yukimune Okubo, Wakaba Endo, Takehiko Inui, Noriko Togashi, Soichiro Tanaka, Yasuko Kobayashi, Akira Onuma, Jun Takayama, Gen Tamiya, Atsuo Kikuchi, Shigeo Kure, and Kazuhiro Haginoya. Two siblings with cerebellar ataxia, mental retardation, and disequilibrium syndrome 4 and a novel variant of atp8a2. The Tohoku journal of experimental medicine, 256:321-326, Mar 2022. URL: https://doi.org/10.1620/tjem.2022.j010, doi:10.1620/tjem.2022.j010. This article has 13 citations.

7. (hochman2025cerebellarataxiaimpaired pages 1-2): Livia Hochman, Alrick Drummond, and Kara Morgan. Cerebellar ataxia, impaired intellectual development, and disequilibrium syndrome-2: a case report. Cureus, Jan 2025. URL: https://doi.org/10.7759/cureus.78066, doi:10.7759/cureus.78066. This article has 0 citations.

8. (wali2021broadeningtheclinical pages 1-2): Gurusidheshwar M. Wali and Gautam Wali. Broadening the clinical spectrum of very low density lipoprotein receptor associated dysequilibrium syndrome. Movement Disorders Clinical Practice, 8:619-623, May 2021. URL: https://doi.org/10.1002/mdc3.13184, doi:10.1002/mdc3.13184. This article has 2 citations and is from a peer-reviewed journal.

9. (beaudin2019thenosologyof pages 57-57): M Beaudin. The nosology of hereditary cerebellar ataxias: development of a classification for recessive ataxias and phenotypical description of spinocerebellar ataxia 34. Unknown journal, 2019.

10. (teov2023compoundheterozygosityin pages 1-3): Bojan Teov, Aleksandra Janchevska, Ardiana Beqiri-Jasari, Velibor Tasic, Goran Kungulovski, and Zoran Gucev. Compound heterozygosity in cerebellar ataxia, mental retardation, and disequilibrium syndrome type 4. PRILOZI, 44:85-90, Dec 2023. URL: https://doi.org/10.2478/prilozi-2023-0051, doi:10.2478/prilozi-2023-0051. This article has 0 citations.

11. (richmond2020cerebellarataxiawith pages 6-11): Christopher M. Richmond, Richard Leventer, Monique M. Ryan, and Martin B. Delatycki. Cerebellar ataxia with normal intellect associated with a homozygous truncating variant in ca8. Clinical Genetics, 97:516-520, Nov 2020. URL: https://doi.org/10.1111/cge.13666, doi:10.1111/cge.13666. This article has 6 citations and is from a peer-reviewed journal.

12. (ali2012amissensefounder pages 1-3): Bassam R Ali, Jennifer L Silhavy, Matthew J Gleeson, Joseph G Gleeson, and Lihadh Al-Gazali. A missense founder mutation in vldlr is associated with dysequilibrium syndrome without quadrupedal locomotion. BMC Medical Genetics, 13:80-80, Sep 2012. URL: https://doi.org/10.1186/1471-2350-13-80, doi:10.1186/1471-2350-13-80. This article has 44 citations and is from a peer-reviewed journal.

13. (narishige2022twosiblingswith pages 4-5): Yuta Narishige, Hisao Yaoita, Moriei Shibuya, Miki Ikeda, Kaori Kodama, Aritomo Kawashima, Yukimune Okubo, Wakaba Endo, Takehiko Inui, Noriko Togashi, Soichiro Tanaka, Yasuko Kobayashi, Akira Onuma, Jun Takayama, Gen Tamiya, Atsuo Kikuchi, Shigeo Kure, and Kazuhiro Haginoya. Two siblings with cerebellar ataxia, mental retardation, and disequilibrium syndrome 4 and a novel variant of atp8a2. The Tohoku journal of experimental medicine, 256:321-326, Mar 2022. URL: https://doi.org/10.1620/tjem.2022.j010, doi:10.1620/tjem.2022.j010. This article has 13 citations.

14. (micalizzi2016verymildfeatures pages 1-2): Alessia Micalizzi, Isabella Moroni, Monia Ginevrino, Tommaso Biagini, Tommaso Mazza, Marta Romani, and Enza Maria Valente. Very mild features of dysequilibrium syndrome associated with a novel vldlr missense mutation. neurogenetics, 17:191-195, Jun 2016. URL: https://doi.org/10.1007/s10048-016-0488-y, doi:10.1007/s10048-016-0488-y. This article has 10 citations and is from a peer-reviewed journal.

15. (boycott2009mutationsinvldlr media 6fdfc298): Kym M. Boycott, Carsten Bonnemann, Joachim Herz, Stephanie Neuert, Chandree Beaulieu, James N. Scott, Anuradha Venkatasubramanian, and Jillian S. Parboosingh. Mutations in vldlr as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome). Journal of Child Neurology, 24:1310-1315, Mar 2009. URL: https://doi.org/10.1177/0883073809332696, doi:10.1177/0883073809332696. This article has 80 citations and is from a peer-reviewed journal.

16. (narishige2022twosiblingswith pages 2-4): Yuta Narishige, Hisao Yaoita, Moriei Shibuya, Miki Ikeda, Kaori Kodama, Aritomo Kawashima, Yukimune Okubo, Wakaba Endo, Takehiko Inui, Noriko Togashi, Soichiro Tanaka, Yasuko Kobayashi, Akira Onuma, Jun Takayama, Gen Tamiya, Atsuo Kikuchi, Shigeo Kure, and Kazuhiro Haginoya. Two siblings with cerebellar ataxia, mental retardation, and disequilibrium syndrome 4 and a novel variant of atp8a2. The Tohoku journal of experimental medicine, 256:321-326, Mar 2022. URL: https://doi.org/10.1620/tjem.2022.j010, doi:10.1620/tjem.2022.j010. This article has 13 citations.

17. (flannery2024anovelmissense pages 1-5): Kyle P. Flannery, Sylvia Safwat, Eli Matsell, Namarata Battula, Ahlam A. A. Hamed, Inaam N. Mohamed, Maha A. Elseed, Mahmoud Koko, Rayan Abubaker, Fatima Abozar, Liena E. O. Elsayed, Vikram Bhise, Robert S. Molday, Mustafa A. Salih, Ashraf Yahia, and M. Chiara Manzini. A novel missense variant in the atpase domain of atp8a2 and review of phenotypic variability of atp8a2-related disorders caused by missense changes. Neurogenetics, 25:425-433, Jul 2024. URL: https://doi.org/10.1007/s10048-024-00773-9, doi:10.1007/s10048-024-00773-9. This article has 6 citations and is from a peer-reviewed journal.

18. (matsell2024functionalandin pages 1-3): Eli Matsell, Jens Peter Andersen, and Robert S. Molday. Functional and in silico analysis of atp8a2 and other p4-atpase variants associated with human genetic diseases. Disease Models & Mechanisms, Apr 2024. URL: https://doi.org/10.1242/dmm.050546, doi:10.1242/dmm.050546. This article has 9 citations and is from a domain leading peer-reviewed journal.

19. (matsell2025characterizingthefunctiona pages 108-112): EW Matsell. Characterizing the function of atp8a2 and its role in neurodegenerative disease. Unknown journal, 2025.

20. (onat2012identificationofatp8a2a pages 155-159): OE Onat. Identification of atp8a2 gene mutation in a consaguineous family segregating cerebellar atrophy and quadrupedal gait. Unknown journal, 2012.

21. (paternoster2020novelhomozygousvariant pages 1-2): Lionel Paternoster, Julie Soblet, Alec Aeby, Xavier De Tiège, Serge Goldman, Wyatt W. Yue, Sandra Coppens, Guillaume Smits, Catheline Vilain, and Nicolas Deconinck. Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3. American Journal of Medical Genetics Part A, 182:2685-2693, Aug 2020. URL: https://doi.org/10.1002/ajmg.a.61805, doi:10.1002/ajmg.a.61805. This article has 4 citations.

22. (alsahli2018furtherdelineationof pages 3-5): Saud Alsahli, Muhammad Talal Alrifai, Saeed Al Tala, Fuad Al Mutairi, and Majid Alfadhel. Further delineation of the clinical phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome type 4. Journal of Central Nervous System Disease, Feb 2018. URL: https://doi.org/10.1177/1179573518759682, doi:10.1177/1179573518759682. This article has 30 citations and is from a peer-reviewed journal.

23. (hochman2025cerebellarataxiaimpaired pages 2-3): Livia Hochman, Alrick Drummond, and Kara Morgan. Cerebellar ataxia, impaired intellectual development, and disequilibrium syndrome-2: a case report. Cureus, Jan 2025. URL: https://doi.org/10.7759/cureus.78066, doi:10.7759/cureus.78066. This article has 0 citations.

24. (onat2012identificationofatp8a2 pages 155-159): OE Onat. Identification of atp8a2 gene mutation in a consaguineous family segregating cerebellar atrophy and quadrupedal gait. Unknown journal, 2012.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03